Baseline characteristics of patients with ITP at the time of vaccinations with S pneumonia and Hib vaccines
| Characteristics . | Rituximab (n = 17) . | Placebo (n = 7) . |
|---|---|---|
| Median age, y (Q1, Q3)* | 40 (37, 66) | 40 (35, 63) |
| Female, N (%) | 12 (71) | 5 (71) |
| Platelet count, × 109/L median (Q1, Q3) | 115 (26, 221) | 42 (30, 208) |
| ITP treatments during the 4 weeks before vaccinations | ||
| Intravenous immune globulin, N | 1 | 0 |
| Prednisone, N | 1 | 1 |
| Danazol, N | 1 | 1 |
| Characteristics . | Rituximab (n = 17) . | Placebo (n = 7) . |
|---|---|---|
| Median age, y (Q1, Q3)* | 40 (37, 66) | 40 (35, 63) |
| Female, N (%) | 12 (71) | 5 (71) |
| Platelet count, × 109/L median (Q1, Q3) | 115 (26, 221) | 42 (30, 208) |
| ITP treatments during the 4 weeks before vaccinations | ||
| Intravenous immune globulin, N | 1 | 0 |
| Prednisone, N | 1 | 1 |
| Danazol, N | 1 | 1 |
Patients had received rituximab or placebo 6 months earlier as part of a randomized clinical trial.
Q1 and Q3 are the first and third quartiles.